Prostate cancer | pharmaphorum

Wednesday 1 April 2026

Prostate cancer

News

J&J claims first approval for PARP combo Akeega

J&J claims first approval for PARP combo Akeega

Johnson & Johnson has picked up its first regulatory approval worldwide for Akeega, a fixed-dose combination of a PARP inhibitor and anti-androgen therapy, as a treatm

News

Lynparza gets OK for use in prostate, breast cancers on NHS

Lynparza gets OK for use in prostate, breast cancers on NHS

AstraZeneca and Merck & Co’s Lynparza will be made available to prostate and breast cancer patients in England and Wales, after cost-effectiveness assessor NICE backed

News

Merck drops last phase 3 Keytruda trial in prostate cancer

Merck drops last phase 3 Keytruda trial in prostate cancer

KEYNOTE-641 showed no benefit when added to Xtandi for castration-resistant prostate cancer.

News

EMA decision

J&J gets restricted label for PARP drug Akeega in EU

Drug is backed for BRCA+ prostate cancer patients only, a narrower group than rival Lynparza.

Oncology

prostate cancer

Time to level the playing field for men with prostate cancer

Prostate cancer affects not just patients, but their families too.

News

prostate cancer blue ribbon

Lynparza under siege in first-line prostate cancer

New data from Pfizer and J&J encroach on AZ and Merck's territory with the PARP inhibitor.